---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-074003"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:42:00.849134+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma President & CSO Oncology resigns; Board disputes severance claim

## Summary
- Steven M. Fruchtman resigned as President and Chief Scientific Officer, Oncology, effective June 17, 2024.
- Fruchtman's attorney claims resignation is for 'good reason' under employment agreement, expecting severance related to change in control.
- Board accepted resignation immediately but disagrees with characterization; believes no severance payments are due.
- Victor Moyo continues as Chief Medical Officer, Oncology.

## SEC filing metadata
- accession: 0001104659-24-074003
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465924074003/0001104659-24-074003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465924074003/tm2417729d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-074003
- JSON: https://secwatch.observer/filing/0001104659-24-074003.json
- Plain text: https://secwatch.observer/filing/0001104659-24-074003.txt

## Key facts
- Executive change
  Steven M. Fruchtman resigned as President and Chief Scientific Officer, Oncology at Traws Pharma, Inc..
  - Action: resigned
  - Role: President and Chief Scientific Officer, Oncology
  source text: On June 17, 2024, Steven M. Fruchtman informed the board of directors (the “Board”) of Traws Pharma, Inc. (the “Company”) of his intent to resign from his positions of President and Chief Scientific Officer, Oncology.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465924074003/0001104659-24-074003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.